Duchenne muscular dystrophy

Duchenne muscular dystrophy, an X‐linked disorder, has an incidence of one in 5000 boys and presents in early childhood with proximal muscle weakness. Untreated boys become wheelchair bound by the age of 12 years and die of cardiorespiratory complications in their late teens to early 20s. The use of corticosteroids, non‐invasive respiratory support, and active surveillance and management of associated complications have improved ambulation, function, quality of life and life expectancy. The clinical features, investigations and management of Duchenne muscular dystrophy are reviewed, as well as the latest in some of the novel therapies.

[1]  K. Lim,et al.  Eteplirsen in the treatment of Duchenne muscular dystrophy , 2017, Drug design, development and therapy.

[2]  V. Ricotti,et al.  Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study , 2014, The Lancet Neurology.

[3]  G. Comi,et al.  Ataluren treatment of patients with nonsense mutation dystrophinopathy , 2014, Muscle & nerve.

[4]  V. Forin,et al.  Respiratory muscle decline in duchenne muscular dystrophy , 2014, Pediatric pulmonology.

[5]  Cardiovascular Health Supervision for Individuals Affected by Duchenne or Becker Muscular Dystrophy (Clinical Report) , 2013, Pediatric Clinical Practice Guidelines & Policies.

[6]  Rachel Salmon,et al.  Newborn bloodspot screening for Duchenne Muscular Dystrophy: 21 years experience in Wales (UK) , 2013, European Journal of Human Genetics.

[7]  G. Piluso,et al.  Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients , 2012, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[8]  T. Grimm,et al.  Survival in Duchenne muscular dystrophy , 2012, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[9]  Cindy Hamil,et al.  Evidence‐based path to newborn screening for duchenne muscular dystrophy , 2012, Annals of neurology.

[10]  N. Laing,et al.  Molecular diagnosis of duchenne muscular dystrophy: past, present and future in relation to implementing therapies. , 2011, The Clinical biochemist. Reviews.

[11]  K. Davies,et al.  Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  J. Bach,et al.  The respiratory management of patients with duchenne muscular dystrophy: A DMD care considerations working group specialty article , 2010, Pediatric pulmonology.

[13]  D. Bittel,et al.  PRACTICE PARAMETER: EVALUATION OF THE CHILD WITH MICROCEPHALY (AN EVIDENCE-BASED REVIEW): REPORT OF THE QUALITY STANDARDS SUBCOMMITTEE OF THE AMERICAN ACADEMY OF NEUROLOGY AND THE PRACTICE COMMITTEE OF THE CHILD NEUROLOGY SOCIETY , 2010, Neurology.

[14]  Craig McDonald,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care , 2010, The Lancet Neurology.

[15]  R. Finkel,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management , 2010, The Lancet Neurology.

[16]  H. Truby,et al.  A review of nutrition in Duchenne muscular dystrophy. , 2009, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

[17]  J. Vles,et al.  Neuropsychiatric Disorders in Males With Duchenne Muscular Dystrophy: Frequency Rate of Attention-Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder, and Obsessive—Compulsive Disorder , 2008, Journal of child neurology.

[18]  J. Benditt,et al.  American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. , 2007, Chest.

[19]  B. Bissonnette,et al.  Duchenne muscular dystrophy: an old anesthesia problem revisited , 2007, Paediatric anaesthesia.

[20]  John Bourke,et al.  Managing Duchenne muscular dystrophy – The additive effect of spinal surgery and home nocturnal ventilation in improving survival , 2007, Neuromuscular Disorders.

[21]  H. Nagaraja,et al.  Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy , 2007, Neurology.

[22]  Meenal Patel,et al.  PTC124 targets genetic disorders caused by nonsense mutations , 2007, Nature.

[23]  M. Main,et al.  Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. , 2007, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[24]  D. Zurakowski,et al.  Posterior Spinal Fusion for Scoliosis in Duchenne Muscular Dystrophy Diminishes the Rate of Respiratory Decline , 2007, Spine.

[25]  B. Wong,et al.  Effect of Long-term Steroids on Cough Efficiency and Respiratory Muscle Strength in Patients With Duchenne Muscular Dystrophy , 2007, Pediatrics.

[26]  M. Toussaint,et al.  Diurnal ventilation via mouthpiece: survival in end-stage Duchenne patients , 2006, European Respiratory Journal.

[27]  G. van Ommen,et al.  Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame rule , 2006, Muscle & nerve.

[28]  S. Pandya,et al.  Practice parameter: Corticosteroid treatment of Duchenne dystrophy - Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society , 2006 .

[29]  B. Alman,et al.  Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade , 2006, Neuromuscular Disorders.

[30]  D. Matthews,et al.  Corticosteroid Treatment and Functional Improvement in Duchenne Muscular Dystrophy: Long-Term Effect , 2005, American journal of physical medicine & rehabilitation.

[31]  C. Dakin,et al.  Sleep‐related breathing disorder in Duchenne muscular dystrophy: Disease spectrum in the paediatric population , 2005, Journal of paediatrics and child health.

[32]  M. Nolan,et al.  Cardiac assessment in childhood carriers of Duchenne and Becker muscular dystrophies , 2003, Neuromuscular Disorders.

[33]  Colin Chandler,et al.  Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation , 2002, Neuromuscular Disorders.

[34]  T. Voit,et al.  Patterns and predictors of sleep disordered breathing in primary myopathies , 2002, Thorax.

[35]  K. Hood,et al.  Newborn screening for Duchenne muscular dystrophy: a psychosocial study , 2002, Archives of disease in childhood. Fetal and neonatal edition.

[36]  P. Calverley,et al.  Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. , 2001, American journal of respiratory and critical care medicine.

[37]  T. Rando.  The dystrophin–glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies , 2001, Muscle & nerve.

[38]  J. Oosterwijk,et al.  Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy , 1999, Neuromuscular Disorders.

[39]  E Bakker,et al.  Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in the Netherlands: a cohort study , 1999, The Lancet.

[40]  L. Politano,et al.  The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. , 1990, International journal of cardiology.

[41]  C. Moseley,et al.  Progression of scoliosis in Duchenne muscular dystrophy. , 1989, The Journal of bone and joint surgery. American volume.

[42]  V. Dubowitz,et al.  Prevention of Rapidly Progressive Scoliosis in Duchenne Muscular Dystrophy by Prolongation of Walking with Orthoses , 1988, Journal of child neurology.

[43]  R. Waterston,et al.  Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. , 1988, The New England journal of medicine.

[44]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[45]  L. Kunkel,et al.  Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy , 1986, Nature.

[46]  V. Dubowitz,et al.  Intellect and Behaviour in Duchenne Muscular Dystrophy , 1981, Developmental medicine and child neurology.

[47]  L. Kunkel,et al.  Chapter 30 – Dystrophinopathies , 2015 .

[48]  Bernard Dan,et al.  Pathophysiology of duchenne muscular dystrophy: current hypotheses. , 2007, Pediatric neurology.

[49]  A. Manzur,et al.  Glucocorticoid corticosteroids for Duchenne muscular dystrophy. , 2004, The Cochrane database of systematic reviews.